ADmit Therapeutics

admit-therapeutics.com ↗ ·Esplugues de Llobregat ·Series A

ADmit Therapeutics is a Barcelona-area biotech company, spun off from the Bellvitge Biomedical Research Institute (IDIBELL) in 2017, that develops MAP-AD, a CE-marked in vitro prognostic blood test based on a mitochondrial DNA epigenetic biomarker to predict progression from mild cognitive impairment to Alzheimer's disease dementia. It combines blood biomarkers, genetics, and machine learning, and holds CAP/CLIA accreditation and an AEMPS manufacturing license. It closed a €5.4M Series A round in 2023 led by Clave Capital.

Founded

2017

Founders

Total funds raised

€6.4M

SectorsBiotech, Diagnostics, Alzheimer's disease, Digital health Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing

Suggest a correction

Founders

Jordi Gascón

Co-Founder

Marta Barrachina

Co-Founder & CEO

Global models 5

C2N Diagnostics

United States · c2n.com ↗

Blood-based diagnostic company for Alzheimer's disease and brain health, the closest large-scale peer in VC-funded blood biomarker testing.

$84MComparable

Linus Health

United States · linushealth.com ↗

Digital/cognitive screening platform for early detection of Alzheimer's and dementia, same early-diagnosis mission with a different (digital rather than blood) modality.

$76MComparable

Altoida

United States · altoida.com ↗

AI and augmented-reality digital biomarker platform predicting Alzheimer's risk, a close comparable in precision-neurology early detection.

$21MComparable

Diadem

Italy · diademdx.com ↗

European biotech with a CE-marked blood-based prognostic test (AlzoSure Predict) for early Alzheimer's detection, the most directly comparable European peer.

$19MComparable

ALZpath

United States · alzpath.bio ↗

Develops diagnostic blood-based assays and antibodies for Alzheimer's biomarkers, backed by the same ADDF Diagnostics Accelerator that supports ADmit.

$1.9MComparable

In the same niche 48 others

See all in the Start-ups Map →

Universal Diagnostics

Venture Debt · €25.7M

Biohope

Madrid

No stage disclosed · €15M

iPremom

Valencia

Seed · €15M

+42 more →

Notes: Most funded first

Investors 10

Open as list →

Ship2B Ventures

ship2bventures.com

3 rounds, led 2 · 2019–23 Spain

Clave Capital

www.clavemayor.com

Led Series A 2023 Spain

Sabadell Venture Capital

bstartup.bancsabadell.com/en

Led Pre-seed 2019 Spain

Series A 2023 Luxembourg

Alzheimer's Drug Discovery Foundation Diagnostics Accelerator

www.alzdiscovery.org ↗

Series A 2023 United States

Additio Ventures

additiocapital.com ↗

Investor Spain

Funding rounds 3

·1 not counted

Date	Round	Amount	Lead
2023-10-06	Series A (estimated)	€5.4M	Clave Capital +5 more
2020-08-31	Seed (estimated)	€785K	Equity4Good +1 more
2019-03-18	Pre-seed	€200K	BStartup (Banco Sabadell), Equity4Good (Ship2B) +1 more

Not counted (1)

Not counted in totals

2020-08-31 Grant — EIC

News 4

Open as list →

Published	Article
2025-12	El Test MAP-AD® de ADmit Therapeutics obtiene el marcado CE-IVDR, el primer test pronóstico de la demencia por enfermedad de Alzheimer ↗ Biotech Spain 2025-12
2024-11-20	Admit Therapeutics receives accreditation from College of American Pathologists ↗ College of American Pathologists Newsroom 2024-11-20
2024-10-28	ADmit Therapeutics predicts progression to Alzheimer's dementia 14 years in advance ↗ AseBio 2024-10-28
2023-10-05	ADmit therapeutics closes a €5.4 million funding round led by Clave Capital, through its Clave Innohealth f.c.r. fund ↗ AseBio 2023-10-05